KETOCONAZOLE- ketoconazole shampoo, suspension Preferred Pharmaceuticals, Inc.


Ketoconazole Shampoo, 2%

Rx Only

DESCRIPTION

Ketoconazole Shampoo, 2% is a red-orange liquid for topical application, containing the broad spectrum synthetic antifungal agent ketoconazole in a concentration of 2% in an aqueous suspension. It also contains: coconut fatty acid diethanolamide, disodium laureth sulfosuccinate, FD & C Red No. 40, hydrochloric acid, imidurea, laurdimonium hydroxypropyl hydrolyzed collagen, PEG-120 methyl glucose dioleate, purified water, sodium chloride, sodium hydroxide, and sodium lauryl ether sulfate.

Ketoconazole is <u>cis</u>-1-acetyl-4-[4-[[2-(2,4-dichlorophenyl)-2-(1<u>H</u>-imidazol-1-ylmethyl)-1,3dioxolan-4-yl]methoxy] phenyl]piperazine and has the following structural formula:



CLINICAL PHARMACOLOGY

Tinea (pityriasis) versicolor is a non-contagious infection of the skin caused by *Pityrosporum orbiculare (Malassezia furfur)*. This commensal organism is part of the normal skin flora. In susceptible individuals the condition is often recurrent and may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in restoration of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental skin exposure. The rate of recurrence of infection is variable.

Ketoconazole was not detected in plasma in 39 patients who shampooed 4-10 times per week for 6 months, or in 33 patients who shampooed 2-3 times per week for 3-26 months (mean: 16 months).

An exaggerated use washing test on the sensitive antecubital skin of 10 subjects twice daily for five consecutive days showed that the irritancy potential of ketoconazole shampoo, 2% was significantly less than that of 2.5% selenium sulfide shampoo.

A human sensitization test, a phototoxicity study, and a photoallergy study conducted in

38 male and 22 female volunteers showed no contact sensitization of the delayed hypersensitivity type, no phototoxicity and no photoallergenic potential due to ketoconazole shampoo, 2%.

Mode of Action-

Interpretations of *in vivo* studies suggest that ketoconazole impairs the synthesis of ergosterol, which is a vital component of fungal cell membranes. It is postulated, but not proven, that the therapeutic effect of ketoconazole in tinea (pityriasis) versicolor is due to the reduction of *Pityrosporum orbiculare* (*Malassezia furfur*) and that the therapeutic effect in dandruff is due to the reduction of *Pityrosporum ovale*. Support for the therapeutic effect in tinea versicolor comes from a three-arm, parallel, double-blind, placebo controlled study in patients who had moderately severe tinea (pityriasis) versicolor. Successful response rates in the primary efficacy population for each of both three-day and single-day regimens of ketoconazole shampoo, 2% were statistically significantly greater (73% and 69%, respectively) than a placebo regimen (5%). There had been mycological confirmation of fungal disease in all cases at baseline. Mycological clearing rates were 84% and 78%, respectively, for the three-day and one-day regimens of the 2% shampoo and 11% in the placebo regimen. While the differences in the rates of successful response between either of the two active regimens was not.

Microbiology-

Ketoconazole is a broad spectrum synthetic antifungal agent which inhibits the growth of the following common dermatophytes and yeasts by altering the permeability of the cell membrane: dermatophytes: *Trichophyton rubrum, T. mentagrophytes, T. tonsurans, Microsporum canis, M. audouini, M. gypseum* and *Epidermophyton floccosum;* yeasts: *Candida albicans, C. tropicalis, Pityrosporum ovale* (*Malassezia ovale*) and *Pityrosporum orbiculare* (*M. furfur*). Development of resistance by these microorganisms to ketoconazole has not been reported.

INDICATIONS AND USAGE

Ketoconazole Shampoo, 2% is indicated for the treatment of tinea (pityriasis) versicolor caused by or presumed to be caused by *Pityrosporum orbiculare* (also known as *Malassezia furfur* or *M. orbiculare*).

Note: Tinea (pityriasis) versicolor may give rise to hyperpigmented or hypopigmented patches on the trunk which may extend to the neck, arms and upper thighs. Treatment of the infection may not immediately result in normalization of pigment to the affected sites. Normalization of pigment following successful therapy is variable and may take months, depending on individual skin type and incidental sun exposure. Although tinea versicolor is not contagious, it may recur because the organism that causes the disease is part of the normal skin flora.

CONTRAINDICATIONS

Ketoconazole Shampoo, 2% is contraindicated in persons who have known hypersensitivity to the active ingredient or excipients of this formulation.

PRECAUTIONS

Severe hypersensitivity reactions, including anaphylaxis, have been reported during post-marketing use of ketoconazole shampoo, 2%. If a reaction suggesting sensitivity or chemical irritation should occur, use of the medication should be discontinued.

Information for Patients-

Patients should be advised of the following:

- Ketoconazole Shampoo, 2% may be irritating to mucous membranes of the eyes and contact with this area should be avoided.
- The following have been reported with the use of ketoconazole shampoo, 2%: hair discoloration and abnormal hair texture, removal of the curl from permanently waved hair, itching, skin burning sensation and contact dermatitis, hypersensitivity, angioedema, alopecia, rash, urticaria, skin irritation, dry skin, and application site reactions.
- Patients who develop allergic reactions, such as generalized rash, skin reactions, severe swelling, angioedema, or shortness of breath should discontinue Ketoconazole Shampoo, 2% and contact their physician immediately.

Carcinogenesis, Mutagenesis, Impairment of Fertility-

Long-term studies to assess the carcinogenic potential of ketoconazole shampoo, 2% have not been conducted. A long-term feeding study of ketoconazole in Swiss Albino mice and in Wistar rats showed no evidence of oncogenic activity. The dominant lethal mutation test in male and female mice revealed that single oral doses of ketoconazole as high as 80 mg/kg were not genotoxic. The Ames Salmonella microsomal activator assay was also negative.

Pregnancy:

Teratogenic effects:

Pregnancy Category C-

There are no adequate and well-controlled studies in pregnant women. Ketoconazole should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. In humans, ketoconazole is not detected in plasma after chronic shampooing on the scalp.

Ketoconazole has been shown to be teratogenic (syndactylia and oligodactylia) in the rat when given orally in the diet at 80 mg/kg/day (a dose 10 times the maximum recommended human oral dose). However, these effects may be related to maternal toxicity, which was seen at this and higher dose levels.

Nursing Mothers-

There are no adequate and well-controlled studies in nursing women. Ketoconazole is not detected in plasma after chronic shampooing on the scalp. Caution should be exercised when Ketoconazole Shampoo, 2% is administered to a nursing woman.

Pediatric Use-

Safety and effectiveness in children have not been established.

ADVERSE REACTIONS

Clinical Trials Experience

In 11 double-blind trials in 264 patients using ketoconazole shampoo, 2% for the treatment of dandruff or seborrheic dermatitis, an increase in normal hair loss and irritation occurred in less than 1% of patients. In three openlabel safety trials in which 41 patients shampooed 4-10 times weekly for six months, the following adverse experiences each occurred once: abnormal hair texture, scalp pustules, mild dryness of the skin, and itching. As with other shampoos, oiliness and dryness of hair and scalp have been reported. In a double-blind, placebocontrolled trial in which patients with tinea versicolor were treated with either a single application of ketoconazole shampoo, 2% (n=106), a daily application for three consecutive days (n=107), or placebo (n=105), drug-related adverse events occurred in 5 (5%), 7 (7%) and 4 (4%) of patients, respectively. The only events that occurred in more than one patient in any one of the three treatment groups were pruritus, application site reaction, and dry skin; none of these events occurred in more than 3% of the patients in any one of the three groups.

Post-marketing Experience

Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency. The following adverse drug reactions have been identified during post-marketing experience with ketoconazole shampoo, 2%: there have been reports of hair discoloration and abnormal hair texture, itching, skin burning sensation, contact dermatitis, hypersensitivity, angioedema, alopecia, rash, urticaria, skin irritation, dry skin, and application site reactions.

OVERDOSAGE

Ketoconazole Shampoo, 2% is intended for external use only. In the event of accidental ingestion, supportive and symptomatic measures should be employed. Induced emesis and gastric lavage should not be performed to avoid aspiration.

DOSAGE AND ADMINISTRATION

Apply the shampoo to the damp skin of the affected area and a wide margin surrounding this area. Lather, leave in place for 5 minutes, and then rinse off with water.

One application of the shampoo should be sufficient.

HOW SUPPLIED

Ketoconazole Shampoo, 2% is a red-orange liquid and is available as follows:

4 fl. oz. (120 mL) nonbreakable plastic bottle (NDC 68788-9903-1)

STORAGE

Store at 20-25°C (68-77°F) [see USP Controlled Room Temperature]. Protect from light. Made in Israel Manufactured By Perrigo Yeruham, Israel OR Manufactured By Perrigo Bronx, NY 10457 Distributed By Perrigo ® Allegan, MI 49010 www.perrigo.com 4L926RCF5 Rev 03-17 OR 2P326RCF6 Rev 08-14 **Relabeled By: Preferred Pharmaceuticals Inc.**

Package/Label Display Panel

Rx Only Ketoconazole Shampoo, 2% For Topical Application Only 4 FL OZ

Ketoconazole Shampoo 2%	PREFERRED Pharmaceuticals, Inc	CAUTION: Federal law PROHIBITS transfer of this drug to any person other thean the patient for whom it was prescribed	Ketoconazole Shampoo 2% Qty: Ins: Lot#: Bat#: Prod# (NDC):	Log
Generic for Nizoral Shampoo Contains See bottle for full listing Pkg Size: Exp Date: Lot#: Batch#: Ins:		Espanol: Dido en	Ketoconazole Shampoo 2% Oty: Ins: Lot#: Bat#: Prod# (NDC):	Chart
Mfg: Perrigo Company; Allegan, MI Prod#: Warning Store at 20°-25°C (68°-7°F). See DSp Controlled Room Temperature Protect from light Keep finis and all model income detections. ingredulents, and avage information - For topical application only. Rx Only.	Directions English directed on	o diriç	Ketoconazole Shampoo 2% Qty: Insurance NDC: Lot#: Bat#:	Billing
	bi Use as dir package.	Instruce Utilice como el paquete.	Ketoconazole Shampoo 2% Qty: Ins: Lot#: Bat#: Prod# (NDC):	Patient

- -

KETOCONA	ZOLE					
ketoconazole s	hampoo, susp	ension				
Product Info	ormation					
Product Type		HUMAN PRESCRIPTION DRUG	ltem Code (Source)	•)3(NDC:45802-
Route of Admi	nistration	TOPICAL				
Active Ingree	diant/Active	Mojety				
Active Ingredient/Active Moiety					Strongth	Strength
	Ingredient Name Basis of Streng			-	20 mg in 1 mL	
RETOCONAZOLE	KETOCONAZOLE (UNII: R9400W927I) (KETOCONAZOLE - UNII:R9400W927I) KETOCONAZOLE					20 mg m i m
Inactive Ingr	edients					
Ingredient Name						Strength
COCO DIETHANOLAMIDE (UNII: 92005F972D)						
DISODIUM LAUR	ETH SULFOSUC	CINATE (UNII: D6DH1DTN7E)			
FD&C RED NO. 4	0 (UNII: WZ B912	7XOA)				
HYDROCHLORIC	ACID (UNII: QTT)	L7582CB)				
IMIDUREA (UNII: 1	M629807ATL)					
PEG-120 METHY	L GLUCOSE DIO	LEATE (UNII: YM0K64F20V)				
SODIUM CHLORI	DE (UNII: 451W47	/IQ8X)				
SODIUM HYDRO	XIDE (UNII: 55X04	QC32I)				
WATER (UNII: 059QF0KO0R)						
SODIUM LAURET	H-3 SULFATE (L	INII: BPV390UAP0)				
Packaging						
# Item Code	Pa	ackage Description	М	arketing S Date	Start Ma	rketing End Date
1 NDC:68788- 9903-1	120 mL in 1 BO ⁻ Combination Pro	TTLE, PLASTIC; Type 0: Not a oduct	a 01,	/30/2012		

pplication Number or Monograph Citation	Marketing Start Date	Marketing End Date	
A076419	01/30/2012		
-	Citation	Citation Date	

Labeler - Preferred Pharmaceuticals, Inc. (791119022)

Registrant - Preferred Pharmaceuticals, Inc. (791119022)

Establishment

Name	Address	ID/FEI	Business Operations
Preferred Pharmaceuticals, Inc.		791119022	RELABEL(68788-9903)

Revised: 7/2022

Preferred Pharmaceuticals, Inc.